Pharmaceutical/healthcare primer

Hi everyone,

I am a 1st year healthcare analyst from a finance background. Basically know nothing about healthcare but was staffed with our healthcare team. 

Wondering if there is a primer/bible addressing pharmaceutical/healthcare sector? It would be great to learn more about different subsectors like prescription drugs, OTC, brand name drugs, generic drugs, biopharma, etc. and valuation methods.

I realize it is a big ask. I would be grateful if anyone could provide suggestions. My bank has database subscriptions so I could also look into helpful reports.

Thanks in advance.

7 Comments
 

From my experience, there isn't really a primer addressing the sector for many good reasons. The sector is always changing, with innovation, new regulations, new subsidies etc. It is quite difficult to create a primer than is still relevant 1/2/3 years down the road. Might be worth looking into individual research papers addressing a specific issue of healthcare such as pricing and speaking to colleagues who have worked on a certain aspect of healthcare. I would say it is mostly on the job experience rather than being able to simply "read and become an expert". 

 

There is an old DB equity research primer on pharma that covers development, lifecycle… probably from 2012-2013 but golden. You’ll find it on Thomsonone or equivalent with a bit of effort.

Cs had decent CRO coverage a little while back and good sector notes

Rbc initiated cdmos sector last year

Cowen have great thematic reports for pharma / biotech - more advanced and technology focused though.

Gsk spin-off Haleon earlier his year has been covered by all major firms - have a look at initiations for a good OTC read

Alcon spun off from novartis was a major medtech listing, check initiations.

Oxford nanopore IPO for life science / tools. Some good reports from Cowen on this sector too, and also diagnostics.

Siemens healthineers 2018 IPO for some good capital equipment / diagnostics initiations

 

Itaque hic mollitia et laboriosam accusantium quaerat. Ullam cupiditate ea dolores voluptatem aperiam dolor.

Quasi pariatur quam maiores eaque voluptas recusandae modi. Aperiam necessitatibus qui assumenda consequuntur dolor ex. Molestiae omnis et eveniet qui odit nihil sunt. Esse vel in autem ut. Nobis aliquam ut nostrum molestiae et aut corrupti delectus.

Ex molestias consequatur vel optio sapiente ut labore rerum. Facilis nostrum beatae consequatur. Fuga magni facilis accusantium mollitia reiciendis repellendus nostrum.

Career Advancement Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Morgan Stanley 07 97.9%
  • Goldman Sachs 02 97.3%

Overall Employee Satisfaction

September 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 98.9%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.3%

Total Avg Compensation

September 2026 Investment Banking

  • Vice President (16) $429
  • Associates (53) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (15) $159
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”